Successful treatment of refractory hemophagocytic lymphohistiocytosis complicating Epstein-Barr virus-positive classic Hodgkin lymphoma with rituximab.

J Clin Exp HematopAug 29, 2026 (epub)
Case ReportHematologyOncology (Medical)

Satoshi Ichikawa, Yutaka Suzuki, Yuya Tanaka et al.

✦ AI-curated · Sources linked

Case in brief

A male in his early 70s with advanced EBV-positive mixed-cellularity classic Hodgkin lymphoma presented with cervical lymphadenopathy, fever, and hepatosplenomegaly. Despite initial chemotherapy, he developed hemophagocytic lymphohistiocytosis (HLH) characterized by persistent fever and cytopenia. Administration of rituximab led to rapid resolution of fever and significant improvement in laboratory markers, allowing continuation of chemotherapy, which resulted in a complete response.

Diagnostic / clinical pearl

Rituximab may be an effective adjunctive treatment for refractory HLH associated with EBV-positive classic Hodgkin lymphoma, particularly when standard therapies are insufficient.

Source

PubMed · PMID 42669549

Published in J Clin Exp Hematop. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.